MS-AnergiX: Filed IND to begin Phase I/II trials. ANRG is developing MS-AnergiX with Novo Nordisk A/S.

Anergen Inc. (ANRG), Redwood City, Calif. Product: MS-AnergiX, which combines a peptide epitope of the antigen suspected to be associated with multiple sclerosis with a soluble form of major histocomp...